Zaina Albalawi1,2, Michael Laffin3, Leah Gramlich4,5, Peter Senior4,6, Finlay A McAlister4,7. 1. Department of Medicine, University of Alberta, Edmonton, Canada. Zalbalaw@ualberta.ca. 2. Endocrinology and Metabolism, Alberta Health Services, Edmonton, Canada. Zalbalaw@ualberta.ca. 3. Department of Surgery, University of Alberta, Edmonton, Canada. 4. Department of Medicine, University of Alberta, Edmonton, Canada. 5. Gastroenterology, University of Alberta, Edmonton, Canada. 6. Endocrinology and Metabolism, University of Alberta, Edmonton, Canada. 7. General Internal Medicine, University of Alberta, Edmonton, Canada.
Abstract
BACKGROUND: Prevalence of diabetes in surgical patients is 10-40%. It is well recognized that they have higher rates of complications, and longer stays in hospital compared to patients without diabetes. Enhanced recovery after surgery (ERAS) is an evidence-based multimodal surgical care pathway that improves postoperative complications and length of stay in patients without diabetes. This review evaluates the evidence on whether individuals with diabetes would benefit from ERAS implementation. METHODS: MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE searched with no language restrictions applied. Conference proceedings and bibliographies were reviewed. Experts in the field were contacted, and www.clinicaltrials.gov searched for ongoing trials. SELECTION CRITERIA: Randomized controlled trials (RCT) looking at individuals with diabetes undergoing surgery randomized to ERAS® or conventional care. Non-randomized controlled trials, controlled before-after studies, interrupted time series, and cohort studies with concurrent controls were also considered. Two authors independently screened studies. RESULTS: The electronic search yielded 437 references. After removing duplicates, 376 were screened for eligibility. Conference proceedings and bibliographies identified additional references. Searching www.clinicaltrials.gov yielded 59 references. Contacting experts in the field identified no further studies. Fourteen full articles were assessed and subsequently excluded for the following reasons: used an intervention other than ERAS®, did not include patients with diabetes, or used an uncontrolled observational design. CONCLUSIONS: To date, the effects of ERAS® on patients with diabetes have not been rigorously evaluated. This review highlights the lack of evidence in this area and provides guidance on design for future studies.
BACKGROUND: Prevalence of diabetes in surgical patients is 10-40%. It is well recognized that they have higher rates of complications, and longer stays in hospital compared to patients without diabetes. Enhanced recovery after surgery (ERAS) is an evidence-based multimodal surgical care pathway that improves postoperative complications and length of stay in patients without diabetes. This review evaluates the evidence on whether individuals with diabetes would benefit from ERAS implementation. METHODS: MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE searched with no language restrictions applied. Conference proceedings and bibliographies were reviewed. Experts in the field were contacted, and www.clinicaltrials.gov searched for ongoing trials. SELECTION CRITERIA: Randomized controlled trials (RCT) looking at individuals with diabetes undergoing surgery randomized to ERAS® or conventional care. Non-randomized controlled trials, controlled before-after studies, interrupted time series, and cohort studies with concurrent controls were also considered. Two authors independently screened studies. RESULTS: The electronic search yielded 437 references. After removing duplicates, 376 were screened for eligibility. Conference proceedings and bibliographies identified additional references. Searching www.clinicaltrials.gov yielded 59 references. Contacting experts in the field identified no further studies. Fourteen full articles were assessed and subsequently excluded for the following reasons: used an intervention other than ERAS®, did not include patients with diabetes, or used an uncontrolled observational design. CONCLUSIONS: To date, the effects of ERAS® on patients with diabetes have not been rigorously evaluated. This review highlights the lack of evidence in this area and provides guidance on design for future studies.
Authors: K Dhatariya; N Levy; A Kilvert; B Watson; D Cousins; D Flanagan; L Hilton; C Jairam; K Leyden; A Lipp; D Lobo; M Sinclair-Hammersley; G Rayman Journal: Diabet Med Date: 2012-04 Impact factor: 4.359
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Ana Maria Buchleitner; Montserrat Martínez-Alonso; Marta Hernández; Ivan Solà; Didac Mauricio Journal: Cochrane Database Syst Rev Date: 2012-09-12
Authors: Guillermo E Umpierrez; Dawn Smiley; Kathie Hermayer; Amna Khan; Darin E Olson; Christopher Newton; Sol Jacobs; Monica Rizzo; Limin Peng; David Reyes; Ingrid Pinzon; Maria Eugenia Fereira; Vicky Hunt; Ashwini Gore; Marcos T Toyoshima; Vivian A Fonseca Journal: Diabetes Care Date: 2013-02-22 Impact factor: 19.112
Authors: Luca Gianotti; Uberto Fumagalli Romario; Stefano De Pascale; Jacopo Weindelmayer; Valentina Mengardo; Marta Sandini; Andrea Cossu; Paolo Parise; Riccardo Rosati; Lapo Bencini; Andrea Coratti; Giovanni Colombo; Federica Galli; Stefano Rausei; Francesco Casella; Andrea Sansonetti; Dario Maggioni; Andrea Costanzi; Davide P Bernasconi; Giovanni De Manzoni Journal: World J Surg Date: 2019-10 Impact factor: 3.352